Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; KERATINOCYTE GROWTH-FACTOR; TOTAL-BODY IRRADIATION; NON-HODGKINS-LYMPHOMA; HIGH-DOSE ETOPOSIDE; PREPARATORY REGIMEN; DOUBLE-BLIND; CHEMOTHERAPY; PROPHYLAXIS (1)
- BONE-MINERAL DENSITY; HORMONE REPLACEMENT THERAPY; FRACTURE INTERVENTION TRIAL; VERTEBRAL FRACTURES; AMINOBISPHOSPHONATE ALENDRONATE; ANTIRESORPTIVE AGENTS; RANDOMIZED-TRIAL; ORAL ALENDRONATE; ELDERLY-WOMEN; HIP FRACTURE (1)
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Palifermin For Oral Mucositis After Intensive Therapy For Hematologic Cancers, Ricardo Spielberger, Patrick Stiff, William Bensinger, Teresa Gentile, Daniel Weisdorf, Tarun Kewalramani, Thomas Shea, Saul Yanovich, Keith Hansen, Stephen Noga, John Mccarty, C. Frederick Lemaistre, Eric C. Sung, Bruce R. Blazar, Dieter Elhardt, Mon-Gy Chen, Christos Emmanouilides
Palifermin For Oral Mucositis After Intensive Therapy For Hematologic Cancers, Ricardo Spielberger, Patrick Stiff, William Bensinger, Teresa Gentile, Daniel Weisdorf, Tarun Kewalramani, Thomas Shea, Saul Yanovich, Keith Hansen, Stephen Noga, John Mccarty, C. Frederick Lemaistre, Eric C. Sung, Bruce R. Blazar, Dieter Elhardt, Mon-Gy Chen, Christos Emmanouilides
Internal Medicine Publications
BACKGROUND: Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effective treatment. We tested the ability of palifermin (recombinant human keratinocyte growth factor) to decrease oral mucosal injury induced by cytotoxic therapy. METHODS: This double-blind study compared the effect of palifermin with that of a placebo on the development of oral mucositis in 212 patients with hematologic cancers; 106 patients received palifermin (60 microg per kilogram of body weight per day) and 106 received a placebo intravenously for three consecutive days immediately before the initiation of conditioning therapy (fractionated total-body irradiation plus high-dose chemotherapy) and after autologous …
Ten Years’ Experience With Alendronate For Osteoporosis In Postmenopausal Women, Henry G. Bone, David Hosking, Jean-Pierre Devogelaer, Joseph R. Tucci, Ronald D. Emkey, Richard P. Tornino, Jose A. Rodriguez-Portales , M.D., Robert W. Downs, Jayanti Gupta, Arthur C. Santora, Uri A. Liberman
Ten Years’ Experience With Alendronate For Osteoporosis In Postmenopausal Women, Henry G. Bone, David Hosking, Jean-Pierre Devogelaer, Joseph R. Tucci, Ronald D. Emkey, Richard P. Tornino, Jose A. Rodriguez-Portales , M.D., Robert W. Downs, Jayanti Gupta, Arthur C. Santora, Uri A. Liberman
Internal Medicine Publications
Background
Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years.
Methods
The initial three-year phase of the study compared three daily doses of alendronate with placebo. Women in the original placebo group received alendronate in years 4 and 5 and then were discharged. Women in the original active-treatment groups continued to receive alendronate during the initial extension (years 4 and 5). In two further extensions (years 6 and 7, and 8 through 10), women who had …